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Poster Session I S197autologous patients that failed prior collection attempts with filgras-
tim (G-CSF) alone. Many centers use plerixafor for prior failed
mobilization on the evening of day 4 of G-CSF. Less consensus
regarding the utilization and timing of plerixafor with current inef-
fective mobilization exists. We developed a strategy utilizing dou-
ble-dose G-CSF on day 4 if the CD34 count was less than 10
cells/mL in an attempt to increase the CD34 count to sufficient levels
to initiate HPC-A, thus obviating the need for plerixafor.
Methods: All patients undergoing HPC-A collections from April
2009 to May 2010 were reviewed. The predefined protocol was as
follows:
All patients started G-CSF 10mcg/kg SQ on day 1.
CD34 cell counts were drawn day 4 of G-CSF.
 If the CD34 cell count $ 10, proceed with HPC-A.
 If\10, an additional evening dose ofG-CSF10mcg/kgwas added.
CD34 cell counts repeated day 5.
 If$ 10, proceedwithHPC-A and continue twice dailyG-CSF un-
til the desired CD34 count.
 If the count 1 to 9, G-CSF revert back to once daily and plerixafor
was added the evening of day 5 with HPC-A the next morning.
 If\ 1, the mobilization attempt was deemed a failure.
Minimum collection goal was 3  106/kg CD34.
Results: 86 patients underwent stem collection, of which 69 fol-
lowed our G-CSF-alone protocol. All 69 were successfully mobi-
lized, 41 (59%) with G-CSF 10mcg/kg SQ daily alone. Of the
remaining 28, 18 (64%) mobilized with twice daily G-CSF and 10
(36%) required plerixafor.
Table 1.
MeanN
Mean
CD34/kg
Mean
HPC-A Days
Cost per
Mobilzation*Daily G-CSF alone 41 8.15 1.98 $14,757
BID G-CSF 18 6.35 3.17 $23,724
Plerixafor + G-CSF 10 6.45 2.80 $35,863*HPC-A cost of $6000/day and hospital acquisition cost utilized for
G-CSF and plerixafor.Cost savings utilizing our strategy versus plerix-
afor on day 4 was $219,000 including drug and HPC-A procedure
costs.This translates to a cost savings of approximately $8,000per pa-
tient.
Conclusion: Doubling the G-CSF frequency to twice daily on day 4
when theCD34 countwas 1- 10was effective inmobilizing 64%of pa-
tients who failed G-CSF-alone mobilization in a similar number of
HPC-Adays (3.17 vs 2.80) when compared to plerixafor. This strategy
results in a significant cost avoidance of approximately $8,000 per pa-
tient. Consideration should be given to double-dose G-CSF on day 4
of current ineffective mobilization in lieu of plerixafor.118
PRELIMINARY EXPERIENCE WITH PLERIXAFOR FOR PERIPHERAL
BLOOD STEM CELL MOBILIZATION IN PEDIATRIC PATIENTS
Hawks, R.G.1, Semidei-Pomales, M.2, Abendroth, H.E.1, Garvin, J.H.1,
Cairo, M.S.1,2,3 1Pediatrics; 2Medicine; 3Columbia University, New
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Autologous peripheral blood stem cell (PBSC) transplant is an ac-
cepted therapy for pediatric patients with lymphoma, neuroblas-
toma, and CNS tumors. PBSC mobilization with filgrastim alone
or filgrastim following chemotherapy may be unsuccessful in heavily
pretreated patients, based on a desired minimum cell count of 2x
10E6 CD341/kg to proceed with Autologous PBSC transplant.
Plerixafor is approved for use in combination with filgrastim for
PBSCmobilization, and in adults with lymphoma or myeloma, pler-
ixafor/filgrastim mobilization results in 2- to 3-fold increased likeli-
hood of successful harvest compared to filgrastim alone. We report
our experience with plerixafor, utilizing a dose of 240 micrograms/
kg SQ 10 -11 hours before pheresis, repeated daily up to 4 days, in7 pediatric patients (3 refractory Burkitt lymphoma (BL), 1 high
risk neuroblastoma (NB), 2 medulloblastoma (MB), 1 recurrent
CNS PNET), ages 10 to 20 years, with inadequate or borderline
PBSC yields following multiagent chemotherapy and filgrastim. In-
cremental PBSC yields following filgrastim and plerixafor were 0 to
9.0  10E6 CD341 cells/kg. The Peripheral Blood CD341 counts
varied widely from . 1.0 to 56 cells/uL. 2 of 3 BL patients and the
NB patient mobilized successfully and underwent autotransplant. 1
BL patient failed to mobilize and underwent allogeneic transplant.
Of 3 CNS tumor patients (all with prior craniospinal irradiation),
1 with MB and 1 with PNET had successful mobilization but died
of disease progression prior to autotransplant; the other patient
with MB continues on reinduction chemotherapy. No serious ad-
verse events were seen.We conclude that plerixafor is safe and effec-
tive in selected pediatric patients even following craniospinal
irradiation, butmay be less effective in refractory patients with exten-
sive prior chemotherapy. The latter group could potentially benefit
from earlier introduction of plerixafor at the first attempted PBSC
mobilization.119
DEFIBROTIDE PREVENTS THE ACTIVATION OF MACROVASCULAR AND
MICROVASCULAR ENDOTHELIA CAUSED BY THE SOLUBLE FACTORS RE-
LEASED TO BLOOD BY AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Diaz-Ricart, M.1, Palomo, M.1, Rovira, M.2, Escolar, G.1, Carreras, E.2
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Endothelial activation and damage occur in association with autol-
ogous hematopoietic stem cell transplantation (HSCT). Several of
the early complications associated withHSCT seem to have amicro-
vascular location. Through the present study, we have characterized
the activation and damage of endothelial cells of both macro
(HUVEC) and microvascular (HMEC) origin, occurring early after
autologous HSCT, and the potential protective effect of defibrotide
(DF). Sera samples from patients were collected before conditioning
(Pre), at the time of transplantation (day 0), and at days 7, 14 and 21
after autologous HSCT. Changes in the expression of endothelial
cell receptors at the surface, presence and reactivity of extracellular
adhesive proteins, and the signaling pathways involved were
analyzed. The expression of ICAM-1 at the cell surface increased
progressively in both HUVEC and HMEC. However, a more pro-
thrombotic profile was denoted for HMEC, in particular at the
time of transplantation (day 0), reflecting the deleterious effect of
the conditioning treatment on the endothelium, especially at amicro-
vascular location. Interestingly, this observation correlated with
a higher increase in the expression of both tissue factor and vonWil-
lebrand factor on the extracellular matrix, together with activation of
intracellular p38 MAPK and Akt. Previous exposure and continuous
incubation of cells with DF prevented the signs of activation and
damage induced by the autologous sera. These observations corrob-
orate that conditioning treatment in autologous HSCT induces
a proinflammatory and a prothrombotic phenotype, specially at
a microvascular location, and indicate that DF has protective antiin-
flammatory and antithrombotic effects in this setting.120
EFFICACY AND COST-BENEFIT ANALYSIS OF PLERIXAFOR PLUS
FILGRASTIM BASED ON A RISK ADAPTIVE APPROACH FOR AUTOLOGOUS
PERIPHERAL BLOOD HEMATOPOIETIC PROGENITOR CELL COLLECTION
Vishnu, P.1, Roy, V.1, Paulsen, A.2, Zubair, A.C.2 1Mayo Clinic,
Jacksonville, FL; 2Mayo Clinic, Jacksonville, FL
Plerixafor (P) in combination with filgrastim (F) is currently ap-
proved for mobilization of hematopoietic progenitor cells (HPC) in
patients with multiple myeloma (MM) or non-hodgkin’s lymphoma
(NHL). F1 P is a very expensive but reduces the incidence of mobi-
lization failure. In an effort to utilize P in a cost efficient manner, we
employed a risk adaptive strategy of using P only in patients who are at
high risk of mobilization failure defined by peripheral blood CD341
S198 Poster Session Icell (pCD34) count of\10/mL after 4 days of F alone. In this studywe
present the results of efficacy and an estimate of cost of such a risk
adaptive strategy for autologous peripheral blood HPC collection.
42 patients with history of NHL orMMundergoing peripheral blood
HPCmobilization fromFebruary toDecember 2009were included in
the analysis. All patients received daily filgrastim for 4 days. Our risk
adaptive approach was to add P for those ‘at-risk’ patients, who on day
4 had a pCD34 count of\10/mL,with apheresis commencing the fol-
lowing morning. Morning administration of F and evening dosing of
Pwas continued daily in this group of ‘at-risk’ patients for up to amax-
imum of 4 days or until. 5 106 CD341 cells/kgwere collected. Re-
sults of consecutive patients who had peripheral blood HPC
mobilization were prospectively collected. A decision analytic model
was created to estimate the mean cost and effectiveness rates in pa-
tients who underwent mobilization with F versus F 1 P. 18 patients
were mobilized with F alone and 24 patients required F1 P. Admin-
istration of P was safe and no severe adverse events were recorded. Ad-
dition of P increased the pCD34 count by 6.8 fold with an average
total yield of 4.9  106 CD341 cells/kg. The frequency of poor mo-
bilization among F only and F1 P patients was 25% and 7% respec-
tively. The pooled average cost benefit for mobilization with F 1 P
may be up to $ 16,900 per patient and could potentially increase the
annual number of transplants by more than 18%. Following autolo-
gous stem cell infusion, days to neutrophil and platelet engraftments
were similar between the patients who mobilized HPC with F versus
F 1 P (p5 0.12). These results suggest that addition of P to F based
on a risk adaptive strategy significantly reduces the frequency of mo-
bilization failures and is also cost effective. Addition of P to F forHPC
mobilization has no significant impact on the neutrophil and platelet
engraftment.121
NEUTROPENIC ENTEROCOLITIS (NE) IN ADULT PATIENTS (PTS)
UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT):
IMPACT OF BOWEL WALL THICKNESS ON CLINICAL OUTCOMES
Jimenez, A.M.1, Vasoo, S.2, Maciejewski, J.1, Rich, E.S.1, Karmali, R.1,
Venugopal, P.1, Gregory, S.A.1, Fung, H.C.1, Nathan, S.1 1Rush
University Medical Center, Chicago, IL; 2Rush University Medical
Center, Chicago, IL
Background: NE is an acute, life-threatening condition character-
ized by transmural inflammation of the intestinal wall in severely
myelosuppressed patients. Although initially described in pediatric
leukemia pts it has increasingly been reported in adults with a variety
of malignant conditions and in the setting of immunosuppression
with HSCT. The aim of this retrospective study was to evaluate
the prognostic value of clinical and radiographic findings in HSCT
recipients diagnosed with NE.
Patients and Methods: Data from 264 HSCT recipients over a 5
year period was reviewed. 24 pts with a clinical diagnosis of NE
supported by the triad of fever, abdominal pain and neutropenia
with radiographic evidence of bowel wall thickening (BWT) were
identified. Degree of BWT by CT scan [mild (m): 3-6 mm, moderate
(M): 6-12 mm and severe (S). 12 mm] along with clinical character-
istics (age, sex, diagnosis, co-morbidities, type of transplant, condi-
tioning regimen and neutropenia length) were evaluated and
correlated with clinical outcomes [complicated (CNE) vs. non-
complicated (cNE)] andmortality. CNEwas defined as those who be-
came bacteremic with enteric flora, required ICU admission or died.
Results: 264 pts underwent a HSCT from 2004 to 2010. A total of
24 (9.1%) pts (average age 52.67 yrs, range 23 – 70yrs) were diag-
nosed with NE. 14 (58.3%) pts underwent an autologous HSCT
and 10 (41.7%) an allogeneic HSCT. Median BWT was 6 mm
(range 2 -15 mm). 11 (45.8%) pts had mBWT, 9 (37.5%) pts
MBWT and 3 (12.5%) pts SBWT. 13(54.2%) pts had cNE and 11
(45.2%) pts had CNE. 7(29.2%) pts required ICU admission and
3 (12.5%) pts died. Clinical characteristics had no impact onmorbid-
ity or mortality in our pt population. Degree of BWT failed to im-
pact mortality on univariate analysis (dead vs. alive: $ 3mm p 5
0.25, $ 6 mm p 5 0.48, $ 12 mm p 5 1.00), but the presence of
MBWT and SBWT ($ 6 mm) was associated with a higher rate
of CNE (CNE vs. cNE: $ 6 mm p 5 0.003 OR:30.0, 95 % CI2.6-342.7). BWT$ 6 mm highly correlated with CNE on multivar-
iate analysis (p 5 0.009 OR:31.5 [2.35-422.3]).
Conclusion: Clinical characteristics had no prognostic impact in
adult patients who developed neutropenic enterocolitis following
HSCT. Patients with moderate and severe bowel thickening have
a worse clinical outcome however this failed to predict mortality;
likely the result of a small sample size. Larger studies and develop-
ment of standardized criteria for bowel thickness measurement are
warranted.122
LONG-TERM FOLLOW-UP OF METASTATIC BREAST CANCER PATIENTS
RECEIVING HIGHLY PURIFIED AUTOLOGOUS CD341THY-11 HEMATO-
POIETIC STEM CELLS AFTER HIGH-DOSE CHEMOTHERAPY
Mueller, A.M.S.1, Kohrt, H.E.K.2, Laport, G.G.1, Negrin, R.S.1,
Cha, S.1, Weissman, I.L.3, Shizuru, J.A.1 1Stanford University, Stan-
ford, CA; 2Stanford University, Stanford, CA; 3Stanford University,
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In the 1990’s high-dose chemotherapy (HDCT) with autologous
hematopoietic cell transplantation (auto-HCT) was considered
a promising, potentially curative treatment approach for patients
(pts) with advanced or metastatic breast cancer (MBC). When ran-
domized trials did not confirm a significant benefit of HDCT over
standard chemotherapy (CTx) enthusiasm for this therapy fell and
transplantation studies ended abruptly. Despite improvements in
overall survival (OS) due to better CTx, endocrine, and immunologic
agents, MBC remains an incurable disease. One potential reason for
the failure ofHDCTwith auto-HCT is the high rate of occult tumor
cell contamination (OTC) in bone marrow, and accordingly in mo-
bilized blood grafts. Here we report the long-term follow-up of 15
pts that underwent HDCT (cisplatin, cyclophosphamide, BCNU)
at our institution between 12/96 and 4/98. FACS-purified
CD341Thy11 hematopoietic stem cells (HSC) with no detectable
tumor contamination (detection level 1/106 cells) were used as
grafts. Of note, 4/15 leukapheresis products contained OTC prior
to sorting. Pts were a median age of 43 years (y), were treated for pri-
mary stage IV BC (n5 5), or relapsed BC (n5 10). Status of remis-
sion at HCT was CR in 47%, and PR and SD in each 26.5% of pts.
More than 12 years after the end of the study 33% pts are alive, 27%
in CR. Median progression-free survival (PFS) is 16 months (m), the
PFS rate at 3y is 47%, at 10y 27%, each. Median OS for the entire
group and for survivors is 120m and 160m, respectively. 5y and
10y OS rates are 60% and 47%, respectively. In comparison, of 78
pts given the same HDCT regimen but unmanipulated grafts, 9%
are alive, and 6% without disease, 71% died of their BC, 22% died
of other reasons, and 4% were lost to follow-up. Median PFS is
9m, and the PFS rates at 3, 5, and 10y are 18%, 11%, and 8%, respec-
tively. Median OS for the entire group was 26m, and 154m for the 7
survivors. OS rates at 3y, 5y and 10y were 39%, 25%, and 13%, re-
spectively. Even though pts numbers in the HSC group are small,
and may include a highly selected population, our data suggest that
infusion of a hematopoietic graft, devoid of OTC, may be critical
to prolong time to relapse, and increase the proportion of CR. We
believe HDCT could regain relevance within multimodal treatment
approaches, as a good remission and avoidance of relapse due to
OTC in the graft could serve as a foundation for treatment with
novel biological and small molecule agents.123
ADAPTIVE RANDOMIZATION FOR BMT CLINICAL TRIALS WITH BOTH
EFFICACY AND FUTILITY OUTCOMES
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Bone marrow transplant (BMT) clinical trials generally feature
fixed randomization schedules determined before patient accrue-
ment. Bayesian adaptive designs based on in-trial treatment
